(Q43131498)

14 November 2017

ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells (English)

1 reference

14 November 2017

J Wu

1

1 reference

14 November 2017

F Meng

2

1 reference

14 November 2017

Y Ying

3

1 reference

14 November 2017

Z Peng

4

1 reference

14 November 2017

L Daniels

5

1 reference

14 November 2017

W G Bornmann

6

1 reference

14 November 2017

A Quintás-Cardama

7

1 reference

14 November 2017

D Roulston

8

1 reference

14 November 2017

M Talpaz

9

1 reference

14 November 2017

L F Peterson

10

1 reference

14 November 2017

N J Donato

11

1 reference

14 November 2017

28 January 2010

1 reference

14 November 2017

1 reference

14 November 2017

24

1 reference

14 November 2017

4

1 reference

14 November 2017

869-872

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2009.300

14 November 2017

0 references

cites work

Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4677994

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4677994

Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4677994

Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4677994

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4677994

Metabolism and disposition of dasatinib after oral administration to humans

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4677994

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4677994

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4677994

15 August 2018

Identifiers

DOI

10.1038/LEU.2009.300

1 reference

Dimensions Publication ID

14 November 2017

0 references

1 reference

14 November 2017

PubMed publication ID

20111070

1 reference